Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic.
Join biopharma colleagues specializing in bioassays, molecular biology, physicochemical properties, quality, process development and regulation across 4 days of niche, expert presentations, and dedicated networking opportunities. This is your must-attend meeting to collaborate ideas, success and challenges to capitalize on the technological advances in analytical development to reach the ultimate goal of bringing safer, efficacious therapies to patients more quickly and effectively.
To know more visit: https://ter.li/qf50s3